Modafinil: A Review of Neurochemical Actions and Effects on Cognition
The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide, Provigil) is an FDA-approved medication with wake-promoting properties. Pre-clinical studies of modafinil suggest a complex profile of neurochemical and behavioral effects, distinct from those of amphetamine. In addition, modafinil shows initial promise for a variety of off-label indications in psychiatry, including treatment-resistant depression, attention-deficit/hyperactivity disorder, and schizophrenia. Cognitive dysfunction may be a particularly important emerging treatment target for modafinil, across these and other neuropsychiatric disorders. We aimed to comprehensively review the empirical literature on neurochemical actions of modafinil, and effects on cognition in animal models, healthy adult humans, and clinical populations. We searched PubMed with the search term 'modafinil' and reviewed all English-language articles for neurochemical, neurophysiological, cognitive, or information-processing experimental measures. We additionally summarized the pharmacokinetic profile of modafinil and clinical efficacy in psychiatric patients. Modafinil exhibits robust effects on catecholamines, serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems in the brain. Many of these effects may be secondary to catecholamine effects, with some selectivity for cortical over subcortical sites of action. In addition, modafinil (at well-tolerated doses) improves function in several cognitive domains, including workin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, side effects of alpha agonists like guanfacine and clonidine include high prevalence of somnolence or sedating effects,168,169”
From Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome (2023) · cites this paper as [168]
In the citing paper
“Modafinil, which is approved by the US Food and Drug Administration for the treatment of narcolepsy and its associated daytime sleepiness [59], is a logical candidate to address the hypoactive/sleepy aspects of CDS.”
Citations
Cites
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472 · cited 7×
“Importantly, modafinil also augments pupillary dilation parameters (Hou et al, 2005) in a manner consistent with LC phasic responses to task-relevant events (Beatty, 1982a, b; Richer and Beatty, 1987), suggesting the potential for LC/NE system effects in optimizing cognitive task performance, as described in the Aston…”
BackgroundMethodResultInfluentialNarcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095 · cited 3×
“m Fos in orexin neurons in perfornical area 150 mg/kg i.p. Immunohisto-chemistry Mice Chemelli et al, 1999 75 mg/kg i.p. Immunohisto-chemistry Rat Scammell et al, 2000 No binding to orexin-1 receptor IC50 410mM 125I-human-orexin B displacement Transfected Chinese Hamster Ovary cells Wieland et al,…”
BackgroundAston-Jones, G., & Bloom, F. (1981) · The Journal of Neuroscience · doi:10.1523/jneurosci.01-08-00876.1981 · Cited by 1,960 · cited 1×
“It appears also that when levels of tonic LC activity are minimal, such as during sleep, grooming, and eating, that phasic responses are also less robust (Aston-Jones and Bloom, 1981).”
BackgroundTask-evoked pupillary responses, processing load, and the structure of processing resources.
Beatty, J. (1982) · Psychological Bulletin · doi:10.1037/0033-2909.91.2.276 · Cited by 1,959 · cited 1×
“…modafinil also augments pupillary dilation parameters (Hou et al, 2005) in a manner consistent with LC phasic responses to task-relevant events (Beatty, 1982a, b; Richer and Beatty, 1987), suggesting the potential for LC/NE system effects in optimizing cognitive task performance, as described…”
The principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 15×
“Inhibition of DA cell firing in VTA/SN; blocked by Sulpiride 10mM but not by Prazosin 20 mM Extracellular recording Rat brain slice Korotkova et al, 2006 Hyperpolarization of VTA neurons, blocked by Sulpiride 10mM 20–50mM Whole-cell patch clamp Isolated VTA neurons No effect on mesencephalic DA neuron activity 128 mg/…”
BackgroundInfluentialDissociation in prefrontal cortex of affective and attentional shifts
Dias, R., Robbins, T. W., & Roberts, A. C. (1996) · Nature · doi:10.1038/380069a0 · Cited by 1,527
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
The role of histamine and the tuberomamillary nucleus in the nervous system
Haas, H., & Panula, P. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1034 · Cited by 929 · cited 5×
“Thalamic NET occupancy: 16, 44% 5, 8 mg/kg i.v. PET with [11C]MeNER Rhesus monkey Madras et al, 2006 NET binding IC50¼ 35.6mM [3H] NE Human Embryo Kidney No effect on pontine NE neuron activity 128 mg/kg i.p. Single-unit recording Rat (anesthetized) Akaoka et al, 1991 Extracellular NE: m in PFC, medial hypothalamus 12…”
BackgroundInfluentialDopaminergic Role in Stimulant-Induced Wakefulness
Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E., & Edgar, D. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01787.2001 · Cited by 769 · cited 7×
“…extracellular DA levels (measured by microdialysis) that are increased significantly in the rat prefrontal cortex (PFC) (de Saint Hilaire et al, 2001), and in the caudate nucleus of narcoleptic dogs (Wisor et al, 2001), although only minimally in the rat hypothalamus (de Saint Hilaire et al, 2001).”
BackgroundInfluentialThe role of locus coeruleus in the regulation of cognitive performance
Usher, M., Cohen, J. D., Servan-Schreiber, D., Rajkowski, J., & Aston-Jones, G. (1999) · Science · doi:10.1126/science.283.5401.549 · Cited by 715
Research works printed but not linked: 1
- Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC et al (1999b). A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 39: 30–40. · DOI · Paper page
Cited by
Items 501–600 of 735
Gründer, G., & Bartsch, T. (2014) · Der Nervenarzt · doi:10.1007/s00115-013-3977-3 · Cited by 13
Countermeasures to the neurocognitive deficits associated with sleep loss
Wesensten, N. J., Hughes, J., & Balkin, T. J. (2011) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2011.03.005 · Cited by 7
Mann, G. S., Ramakrishnan, M., Pakkam, M., Sufiyan, N., Kukadiya, R., & Girigosavi, K. B. (2026) · Sleep Medicine X · doi:10.1016/j.sleepx.2026.100185 · Cited by 5
“Real-world data similarly support its effectiveness, reporting improvements in daily productivity and reduced risk of sleep-related accidents [39].”
Güvel, M. C., Aykan, U., Paykal, G., & Uluoğlu, C. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173793 · Cited by 5
Theodosis‐Nobelos, P., Varra, F., Varras, M. N., & Rekka, E. A. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575360959250117073046 · Cited by 6
Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats
Quisenberry, A. J., & Baker, L. E. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4065-0 · Cited by 5
“As noted above, the DAT is implicated in modafinil’s actions (Minzenberg and Carter 2008; Wisor et al. 2001).”
BackgroundBurrows, B. T., Watterson, L. R., Johnson, M. A., & Olive, M. F. (2015) · Journal of Drug and Alcohol Research · doi:10.4303/jdar/235958 · Cited by 5
“DAT inhibitors [1,11,13,14], with the R-enantiomer having”
BackgroundNeuroimaging of sleep disorders
Nofzinger, E. A., Maquet, P., & Thorpy, M. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139088268.025 · Cited by 5
Carr, Z. J., Vells, B., Wood, B. R., Lowery, J. D., Rogers, A. M., Kunselman, A. A., Karamchandani, K., & Vaida, S. J. (2018) · Medicine · doi:10.1097/md.0000000000012585 · Cited by 5
Neuropsicología clínica en perspectiva: retos futuros basados en desarrollos presentes
Verdejo‐García, A., & Ustárroz, J. T. (2012) · Revista de Neurología · doi:10.33588/rn.5403.2011499 · Cited by 16
Neuroethical Issues in Cognitive Enhancement
Sahakian, B. J., & Morein‐Zamir, S. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130308 · Cited by 6
High-Risk Groups for Charcoal-Burning Suicide Attempt in Hong Kong, China, 2004
Leung, E. L. C.-M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08l04760 · Cited by 5
Lauflumide (NLS-4) Is a New Potent Wake-Promoting Compound
Luca, G., Bandarabadi, M., Konofal, É., Lecendreux, M., Ferrié, L., Figadère, B., & Tafti, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00519 · Cited by 5
CENTRAL SEROUS CHORIORETINOPATHY ASSOCIATED WITH NARCOLEPSY
Kim, J. T., Eichling, P. S., & Wang, M. (2010) · Retinal Cases & Brief Reports · doi:10.1097/icb.0b013e3181f66ac0 · Cited by 5
Bjerring, P. N., Morgan, M. Y., Vilstrup, H., Nielsen, S. M., Christensen, R., & Gluud, L. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013241 · Cited by 5
Stimulant drug effects on touchscreen automated paired-associates learning (PAL) in ratsPreprint
Roschlau, C., Votteler, A., & Hauber, W. (2016) · Learning & Memory · doi:10.1101/lm.040345.115 · Cited by 5
“As the drug doses used here (32, 64 mg / kg) were behaviorally active in various cognitive tasks for rats (Minzenberg and Carter 2008), inappropriate dosing might not account for negative results.”
Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
Venero, C. (2015) · Cognitive Enhancement · doi:10.1016/b978-0-12-417042-1.00010-3 · Cited by 4
Li, J., Zhou, R., Deng, J., Zhou, H., Hu, J., & Wang, X. (2025) · BMC Neurology · doi:10.1186/s12883-025-04526-5 · Cited by 4
“By inhibiting the dopamine transporter, modafinil reduces the reuptake of dopamine and enhances the dopaminergic neurotransmission in the central nervous system of patients with PD, ultimately promoting wake-fulness [51].”
Pharmacological Strategies to Improve Mental Performance
Cutsem, J. V., & Pattyn, N. (2024) · Routledge eBooks · doi:10.4324/9781003378969-8 · Cited by 4
Christensen, J., Vlassopoulos, E., Barlow, C. K., Schittenhelm, R. B., Li, C. N., Sgro, M., Warren, S., Semple, B. D., Yamakawa, G. R., Shultz, S. R., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114969 · Cited by 4
“Given that most of these neurotransmitters have been implicated in modafinil ’ s ‘mechanism ’ of action (Minzenberg and Carter, 2008), modafinil administration in females would likely result in different outcomes.”
BackgroundInfluentialAdenosinergic Regulation of Sleep–Wake Behavior in the Basal Ganglia
Lazarus, M., & Urade, Y. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-20273-0_15 · Cited by 4
Dabiri, M., Tavil, H. E., Lehi, N. F., Movahed, S. K., Salmasi, A. M., & Souri, S. (2021) · Journal of Physics and Chemistry of Solids · doi:10.1016/j.jpcs.2021.110497 · Cited by 4
Seifi, A., Hassannezhad, S., Mosaddeghi-Heris, R., Olia, A. H. K., Adib, A., Hafeez, S., & Barthol, C. A. (2023) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000577 · Cited by 4
Sakayori, T., Ikeda, Y., Arakawa, R., Nogami, T., & Tateno, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-71851-z · Cited by 4
“Modafinil, regulated in the S6 category and which we have previously shown to sufficiently inhibit DAT and stimulate the reward system, has been reported to improve memory and attention 37 , and it is assumed that this effect on brain function is via DAT inhibition 38 .”
BackgroundCognitive enhancement: a brief overview
Outhoff, K. (2016) · South African Family Practice · doi:10.4102/safp.v58i1.4436 · Cited by 4
Haney, M., Rubin, E., Denson, R. K., & Foltin, R. W. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108554 · Cited by 4
The role of eugeroics in the treatment of affective disorders
Urban, A. E., & Cubała, W. J. (2018) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/90687 · Cited by 4
Modafinil Augmentation Therapy in Patient with Traumatic Brain Injury.
Tcheremissine, O. V., & Rachal, J. (2017) · Europe PMC (PubMed Central) · Cited by 4
Stimulants: Definition, Pharmacology, Indications, Side Effects, and Treatment Strategies
Steinbuchel, P. H., & Greenhill, L. L. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_324-1 · Cited by 6
Winter, Y., Lang, C., Kallweit, U., Apel, D., Fleischer, V., Ellwardt, E., & Groppa, S. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.10.005 · Cited by 4
Ron, P. D., Dremier, S., Winlow, P., Jenkins, A., Hanon, É., & da Costa, A. N. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.01.010 · Cited by 4
“European Neuropsychopharmacolo modafinil administration suggests a potential action on dopaminergic neurons, an effect shared with other psychostimulants such as cocaine, methylphenidate and amphetamines (Minzenberg and Carter, 2008).”
BackgroundAttention deficit hyperactivity disorder (ADHD): Improved understanding and novel drug treatment
Marsden, C. A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.016 · Cited by 5
Schmitt, K. C., & Reith, M. E. A. (2012) · PLoS ONE · doi:10.1371/annotation/ba711a7c-13fb-4d18-89a8-28dcc68fcd04 · Cited by 4
Lamas-Aguilar, R., Díaz-Ruiz, A., Navarro, L., Ojeda, R. A. M., Martínez-Cárdenas, M. D. L. Á., Mata-Bermúdez, A., & Ríos, C. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240131121642 · Cited by 4
“…that these drugs improve function in several cognitive domains, including working memory and episodic memory, and other processes that depend on the prefrontal cortex and cognitive control in adults, as well as being well tolerated with a reduced rate of adverse events and risk of dependence [19].”
BackgroundJoão, R. B., Pacheco-Barrios, N. V., Leite, M. G. H. S. J., Soares, Y. R. R. G., Bakir, Z. E., Veiga, M. E., & Dantas, J. M. (2025) · Brain Injury · doi:10.1080/02699052.2025.2502424 · Cited by 3
“In summary, interventions alleviating EDS may indirectly improve related domains, particularly by enhancing wakefulness, sustained attention, and psychomotor vigilance (25,56– 58).”
Pathania, V., Akanksha, M., Majumdar, S., Chowdhury, P. K., & Roy, S. R. (2025) · Green Chemistry · doi:10.1039/d5gc02770e · Cited by 3
Chiappini, S., Gramuglia, P. D., Palagini, L., Miuli, A., Auriacombe, M., & Martinotti, G. (2025) · Psychiatry International · doi:10.3390/psychiatryint6040121 · Cited by 4
Szabadi, E. (2025) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2025.1670564 · Cited by 4
Schneider, L. D., Cairns, A., Ruoff, C. M., & Bogan, R. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11566 · Cited by 3
“…have been posited to explain the symptoms and sleep architecture changes observed in people with idiopathic hypersomnia, pointing to alterations in circadian rhythm, 85,96 GABAergic signaling, 71,94 wake-promoting monoaminergic activity, 95 or brain network connectivity and blood flow alterations.”
Ivanova, E. A., Merkulov, V. G., Gladilina, V. I., Rusakov, S. P., Kuchurov, I. V., Zharkov, M. N., & Zlotin, S. G. (2025) · ACS Omega · doi:10.1021/acsomega.5c02986 · Cited by 3
Ventricular Tachycardia during Treatment with Modafinil for Narcolepsy: A Case Report
Binnenmars, H., Idzerda, H. H. D., Tan, H. L., & Linssen, G. C. M. (2012) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2012.36092 · Cited by 3
“The effects of modafinil are attributed to wake-promoting mechanisms via central dopamine receptors [3-6].”
BackgroundNarcolepsy, How do We Manage it?
Kim, H., & Cho, J. W. (2020) · Journal of Sleep Medicine · doi:10.13078/jsm.200006 · Cited by 3
“기전으로 주간과다졸림증을 줄이는지는 명확하게 밝혀지지 않았으나, 주로 도파민 위주의 모노아민계 시스템(monoaminergic system)과 기타 가바(gamma aminobutyric acid, GABA), 글루타메이트(glutamate) 시스템 등을 통해 효과를 나타내는 것으로 알려져 있다.(7) 모다피닐은 매우 선택적으로 도파민 수용체에 부착하여 도파민 재흡수를 차단시킴으로써 세포 외 도파민 농도를 증가시켜 각성작용을 증진시킨다.”
Rahmani, M. R., Zamanian, M. Y., Karimvandi, M. N., Nikbakhtzadeh, M., Zahedi, E., Bokov, D. O., Kujawska, M., & Heidari, M. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220901122824 · Cited by 3
Stimulants: Definition, Pharmacology, Indications, Side Effects, and Treatment Strategies
Steinbuchel, P. H., & Greenhill, L. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_324 · Cited by 4
Alam, N., & Choudhary, K. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00077 · Cited by 4
Teodorini, R. D., Rycroft, N., & Smith-Spark, J. H. (2024) · Brain and Behavior · doi:10.1002/brb3.3403 · Cited by 4
Insomnia-related rodent models in drug discovery
Chen, Z.-K., Liu, Y., Zhou, J.-C., Chen, G.-H., Liu, C., Qu, W., & Huang, Z. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01269-w · Cited by 3
“Another psychostimulant moda fi nil is also a wake-promoting drug with low abuse potential used in the treatment of sleep-related disorders, such as narcolepsy, shift-work sleep disorder, and obstructive sleep apnea/hypopnea syndrome [168, 169].”
Modafinil: A Candidate for Pharmacotherapy of Negative Symptoms in Schizophrenia
Peloian, J. H., & Pierre, J. M. (2007) · Progress in Neurotherapeutics and Neuropsychopharmacology · doi:10.1017/s1748232107000134 · Cited by 3
Is a Neuroprotective Therapy Suitable for Schizophrenia Patients?
Ritsner, M. S. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_12 · Cited by 3
PRENATAL EXPOSURE TO MODAFINIL ALTERS LOCOMOTOR BEHAVIOUR AND LEUCOCYTE PHAGOCYTOSIS IN MICE
Kučerová, J., Amchová, P., Máchalová, A., Pistovčáková, J., & Šulcová, A. (2018) · Psychiatria Danubina · doi:10.24869/psyd.2018.356 · Cited by 3
“The dose of 50 mg/kg is about 5-times higher than clinically relevant and in preclinical experimentation the doses range up to 600 mg/kg (Minzenberg & Carter 2008).”
BackgroundColzato, L. S., & Mourits, R. (2017) · Springer eBooks · doi:10.1007/978-3-319-57505-6_7 · Cited by 3
Brühl, A. B., & Sahakian, B. J. (2017) · Psychological Medicine · doi:10.1017/s0033291716003603 · Cited by 4
“However, the pharmacological action of modafinil is more complex, involving also a reuptake inhibiting effect for noradrenaline (Minzenberg & Carter, 2008) as well as modulating GABA, serotonin, histamine and orexin (Scoriels et al. 2013), and besides promoting wakefulness, it also has various…”
BackgroundCognitive enhancers versus stimulants
Peters, M. A. K., & Sarter, M. F. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511783005.012 · Cited by 2
Borghgraef, C., Libert, Y., Étienne, A.-M., Delvaux, N., Reynaert, C., & Razavi, D. (2014) · Bulletin du Cancer · doi:10.1684/bdc.2014.1941 · Cited by 2
Flindall, I. R., Leff, D. R., Goodship, J., Sugden, C., & Darzi, A. W. (2015) · Surgery · doi:10.1016/j.surg.2015.09.017 · Cited by 2
Koester, S. W., Rumalla, K., Catapano, J. S., Sorkhi, S. R., Mahadevan, V., Devine, G., Naik, A., Winkler, E. A., Rudy, R. F., Baranoski, J. F., et al. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.02.056 · Cited by 2
Der‐Avakian, A., Barnes, S. A., Lees, T., Schroder, H. S., Kangas, B. D., Linton, S. R., Nickels, S., Robble, M. A., Breiger, M., Iturra-Mena, A. M., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08729-x · Cited by 4
Stable interindividual differences in modafinil’s effect on vigilance during sleep deprivation
Cutsem, J. V., Puyvelde, M. V., van den Berg, N., Dessy, E., Detaille, F., Rompay, A. V., Maîresse, O., Drogou, C., Sauvet, F., Neyt, X., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1607444 · Cited by 2
Saeed, M., Mostafa, N. S., Mahmoud, A. M., Mohamed, A. A., & Elsayed, M. A. (2025) · Luminescence · doi:10.1002/bio.70380 · Cited by 2
Kurtz, A. (2026) · Philosophies · doi:10.3390/philosophies11010014 · Cited by 2
Advances in Non-CPAP Management of Obstructive Sleep Apnea: Spotlight on Pharmacological Therapies
Siciliano, M., de Scisciolo, M., Fratini, A., Sottani, C., Giordani, F., & Brunetti, V. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16020105 · Cited by 2
Effects of modafinil and bromazepam on decision-making: a P300 analysis
Novaes, A., Bittencourt, J., Adolfo, W. B., Gongora, M., Teixeira, S. S., Pompeu, F. A. M. S., Sandoval-Carrillo, A. A., Salas-Pacheco, J. M., Herrera-Solís, A., Basile, L., et al. (2015) · International Archives of Medicine · doi:10.3823/1650 · Cited by 3
“Modafinil is considered to be a cognitive amplifier, capable of modulating functional organization and brain communication, therefore resulting in the improvement of cognitive performance [10-14].”
BackgroundRouse, J. B., Avis, K. T., & Schwebel, D. C. (2021) · Sleep Medicine Research · doi:10.17241/smr.2021.00850 · Cited by 2
“We examined functioning after at least six days of treatment with modafinil, which should be sufficient to induce full neurocognitive effects of the stimulant medication [22], but it is possible that longer-term results would differ if we assessed functioning repeatedly or after several weeks of administration.”
BackgroundEthical Issues in Neuropsychopharmacotherapy: US Perspective
Menconi, M. J., & Dubljević, V. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_380 · Cited by 2
Bussu, G., Portugal, A. M., Wilsson, L., Kleberg, J. L., & Falck‐Ytter, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-49373-x · Cited by 2
“The Yerkes–Dod-son curve linking arousal to cognitive performance in an inverted U -shaped relation has been linked to tonic LC activity 33–35 , which is in line with our post-hoc findings on the inverted U-shaped relation between baseline pupil size (used as an index of tonic arousal) and target…”
ResultLiu, Y., Pu, S., Sun, C., Kai, G., Yu, Y., & Li, H. (2025) · Organic & Biomolecular Chemistry · doi:10.1039/d5ob00249d · Cited by 2
Cosmetic Neurocognitive Enhancement and Healthcare Providers
Gunter, T. D. (2015) · Indiana Health Law Review · doi:10.18060/3911.0007 · Cited by 2
Modafinil effects in narcolepsy
Saletu, M., & Saletu-Zyhlarz, G. M. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139088268.031 · Cited by 2
Brain Protection in Neuropsychiatric Disorders: Past, Present and Future Challenges
Susser, E., & Ritsner, M. S. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_1 · Cited by 3
Contributions from Neuroscience and Neuropsychology
Goudriaan, A. E., van Holst, R. J., Veltman, D. J., & van den Brink, W. (2013) · Wiley eBooks · doi:10.1002/9781118316078.ch3 · Cited by 2
Cognitive Development Considerations for Long-term Safety Exposures in Children
Pipan, M. E., Wang, P. P., & Penna, R. T. (2013) · Wiley eBooks · doi:10.1002/9781118312087.ch30 · Cited by 3
Pharmacological approaches to cognitive enhancement
Harvey, P. D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003872.016 · Cited by 2
The Speculative Neuroscience of the Future Human Brain
Dielenberg, R. A. (2013) · Humanities · doi:10.3390/h2020209 · Cited by 3
“unclear [238,239], although one study has raised the possibility that modafinil affects wakefulness by interacting with catecholamine transporters in brain [240].”
BackgroundThe importance of realism in assessing technological possibilities: The role of Christian thinking
Jones, D. G., & Jones, D. G. (2013) · Cited by 2
(2015) · Advances in Pharmacoepidemiology & Drug Safety · doi:10.4172/2167-1052.1000189 · Cited by 2
“Modafinil is eliminated primarily through the liver with amide hydrolysis and, to a lesser extent, with cytochrome P450 oxidation [23].”
BackgroundInfluentialSoyka, M., & Franke, A. G. (2017) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000484 · Cited by 2
Kooij, J. J. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82812-7_4 · Cited by 2
Pharmacological Cognitive Enhancement: Current Situation and Perspectives
Yamamoto, M. (2022) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.21-00195 · Cited by 2
Philipsen, M. H., Ranjbari, E., Gu, C., & Ewing, A. G. (2021) · Angewandte Chemie · doi:10.1002/ange.202105004 · Cited by 2
Cognitive Enhancers for the Treatment of Anxiety Disorders
Curtiss, J. E., Carpenter, J. K., Kind, S., & Hofmann, S. G. (2016) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780199935291.013.15 · Cited by 2
Stimulants in Bipolar Depression: Risks and Benefits
Núñez, N. A., Salgado, M. F., & Frye, M. A. (2023) · Psychiatric Annals · doi:10.3928/00485713-20230201-01 · Cited by 2
‘Legal highs’ – an experiment at high risk, in terms of provisions of the new Act
Żukiewicz-Sobczak, W. A., Chmielewska–Badora, J., Krasowska, D., Wojtyła, A., Piątek, J., & Zwoliński, J. (2012) · Medycyna Ogólna i Nauki o Zdrowiu · Cited by 2
[Iatrogenic Cushing's syndrome and cortico-dependent gout. (Presentation of a case)].
Errazti, A. R., Pombo, J. L. H., Casado, M. J., & Jl, R.-M. (1965) · PubMed · Cited by 2
Anghelescu, I., & Ahlers, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_128 · Cited by 2
Role of Pharmacological Interventions for Sleep Deprivation
Wesensten, N. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-378610-4.00080-2 · Cited by 2
Teikari, P. (2012) · theses.fr (ABES) · doi:10.70675/96362824z0120z4ed7z94c7zb60f3d7e5f50 · Cited by 5
Borghol, A., Jamero, D. J., Ahmed, F., Hadgu, R. M., Wilson, C., Fabre’-LaCoste, N., Dinh, A., Thompson, J., Castro, M., Paudyal, A., et al. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3150 · Cited by 1
Lights, camera, cognition: Unveiling the Neurocognitive Effects of Modafinil in Actors
Mehr, A. A., Zargar, S., Chelengar, V., & Golkar, M. (2023) · International Journal of Multidisciplinary Research and Growth Evaluation · doi:10.54660/.ijmrge.2023.4.5.721-727 · Cited by 1
Aguiar‐Geraldo, J. M., da Silva, B. S., Possamai‐Della, T., Machado-Laureano, M. L., Vitoreti-Vargas, A., Quevedo, J., & Valvassori, S. S. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01600-2 · Cited by 1
Methylphenidate and Modafinil Mitigate Scopolamine-Induced Behavioral Alterations
Alam, N., Quddoos, S. A., Khatoon, H., Siddiqui, T., & Kashif, S. S. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00618 · Cited by 1
López‐Amador, N. (2025) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2025.1004112 · Cited by 1
Choi, Y. H., Kim, K. M., Kim, B., Kim, H.-J., Kim, S. W., Baik, K., Seok, J. M., Sunwoo, J., Song, I., Woo, H. G., et al. (2025) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2025.0045 · Cited by 1
Potthoff, J., & Hartmann, H. (2025) · Acta Psychologica · doi:10.1016/j.actpsy.2025.106127 · Cited by 1
Ramesh, B., & Kumar, U. S. (2026) · SN Computer Science · doi:10.1007/s42979-026-04902-z · Cited by 1
Adenosine A 1 and A 2A Receptors in Sleep Disorders: Mechanisms and Therapeutic Implications
Jee, H. J., Youn, C., Lee, H., & Jung, Y.-S. (2026) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2026.070 · Cited by 2
“…of modafinil involves inhibition of the dopamine transporter (DAT), resulting in increased extracellular dopamine levels and subsequent activation of downstream arousal systems, including noradrenergic and histaminergic pathways (Hersey and Tanda, 2024; Minzenberg and Carter, 2008; Szabadi, 2025).”
Off-label and investigational drugs in the treatment of gambling disorder: a critical review
Bissig, L., & Mutschler, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1806954 · Cited by 2
“In addition to its dopaminergic effects, modafinil also increases extracellular glutamate levels in various regions of the brain (Minzenberg and Carter, 2008).”
Sahakian, B. J., & Langley, C. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261466620 · Cited by 1
Thorsteinsson, H. S., & Karlsson, K. Æ. (2009) · The Open Sleep Journal · doi:10.2174/1874620900902010048 · Cited by 1
“Specifically, it does not affect blood pressure and has very little effect on neuroendocrine activity [63] [64]; also, repeated use does not seem to induce tolerance or withdrawal [62-64].”
Stimulant Reversal of Cognitive Deficits
Wesensten, N. J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511783005.007 · Cited by 1
Memory Reconsolidation for Treatment-Resistant Aggression and Self-Injurious Behaviors
Matuskey, D., & Sondik, T. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000264 · Cited by 1
Metadata
- Authors
- Minzenberg, M. J., & Carter, C. S.
- Affiliations
- University of California Davis Medical Center (US)
- Corresponding author
- Minzenberg, Michael J
- Venue
- Neuropsychopharmacology
- Published
- 2007-08-22
- Volume
- 33
- Issue
- 7
- Pages
- 1477-1502
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2122011624
- Semantic Scholar
- cf5b2a15296e7832bcfdd965f28583772ef2999c
- Cited by
- 713
- References
- 215
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 25 · 2023: 33 · 2022: 33 · 2021: 46 · 2020: 26 · 2019: 19 · 2018: 33 · 2017: 42 · 2016: 22 · 2015: 49 · 2014: 48 · 2013: 62 · 2012: 59
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 59883, MH066629, R01MH059883, R01MH066629)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Keywords
- modafinil, wakefulness-promoting agents, neurochemical mechanisms, cognition, catecholamines, serotonin, glutamate, GABA, orexin, histamine, working memory, episodic memory, prefrontal cortex, cognitive control, treatment-resistant depression, attention deficit hyperactivity disorder, schizophrenia, cognitive impairment, pharmacokinetics, abuse liability
- MeSH terms
- Modafinil, Animals, Mental Disorders, Benzhydryl Compounds, Brain Chemistry, Cognition, Humans, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.